MDR versus IVDR: Six Structural Differences Manufacturers Must Not Mix Up

1. Key takeaways

The MDR (Regulation (EU) 2017/745) and the IVDR (Regulation (EU) 2017/746) were adopted on the same day and share EUDAMED, the UDI framework and the notified body system, yet six structural differences separate them: classification rules (the 7 rules of Annex VIII under the IVDR versus the 22 rules of Annex VIII under the MDR), evidence type (performance evaluation versus clinical evaluation), the mechanism for tightening scrutiny of high-risk devices (EURL verification plus batch testing versus expert panels plus the clinical evaluation consultation procedure), dates of application (2022-05-26 versus 2021-05-26), transition endpoints (the IVDR runs in three steps to 2029-12-31 while the MDR runs in two steps to 2028-12-31), and the differing provision numbers for economic operator registration and naming details. Companies running both frameworks must treat them as genuinely separate regulatory systems, not as one CE regime with two labels, because most compliance failures observed in practice originate from transplanting assumptions across the two texts.

2. Legal basis

3. Expert insights

Insight 1: The difference in classification rules means experience does not transfer across the two regimes.

IVDR classification looks at the consequences of incorrect information: whether an erroneous result would endanger life, or whether the device carries a risk of transmitting dangerous agents, and the whole system fits into 7 rules. MDR classification looks at device attributes such as invasiveness, duration of use and energy supply, and spreads across 22 rules. Applying MDR classification intuition to an IVD is one of the main sources of classification errors: a low-risk-looking accessory under MDR logic may be Class C or D under IVDR logic because of what a wrong result would mean for a patient. Independent classification documentation for each regime is therefore essential, with the rationale for each rule application recorded so that notified bodies and authorities can follow the reasoning rather than just the outcome.

Insight 2: The difference in evidence type is a difference in the object being evaluated.

Performance evaluation under IVDR Article 56 rests on three pillars, scientific validity, analytical performance and clinical performance, and answers the question of whether the device measures accurately and whether its conclusions are correct. Clinical evaluation under MDR Article 61 answers whether the device is safe and effective when used on patients. Both regimes require data, but the data structures, the literature landscape and the follow-up instruments (PMPF versus PMCF) are entirely different. Templates built for clinical evaluation do not convert into performance evaluation by renaming headings; the underlying evidence plan must be designed separately.

Insight 3: The difference in high-risk mechanisms is a distinctive IVDR cost item.

IVDR Class D devices face an additional layer of laboratory-level verification: the EURL verifies performance and compliance with common specifications under Article 100(2)(a), carries out testing on samples or batches under Article 100(2)(b), and, where no common specifications exist and the device is certified for the first time, experts provide an opinion (Article 48(6)). High-risk devices under the MDR instead go through expert panels and the clinical evaluation consultation procedure. The IVDR adds a physical component, the submission of samples and batch testing, which directly extends project timelines. Manufacturers must budget for this phase explicitly, since MDR experience contains no equivalent step. Scheduling the EURL interaction early in the project, alongside sample availability planning, prevents the laboratory phase from becoming the critical path at the end of the timeline.

Insight 4: The difference in transition endpoints shapes the planning of legacy assets.

According to the tables published by the authorities, legacy devices under the IVDR run in three steps: Class D by 2027-12-31, Class C by 2028-12-31, and Class B and sterile Class A by 2029-12-31; under the MDR they run in two steps: Class III and Class IIb implantables by 2027-12-31 and all other classes by 2028-12-31. Companies with combined MDR and IVDR portfolios, such as companion diagnostics paired with drug delivery devices, must schedule the two transitions separately and must not allow the later endpoint of one regime to be applied to devices falling under the other. Portfolio-level planning that lists every product against its own regulation and endpoint is the simplest safeguard against such misattribution.

4. Practical recommendations

1. For companies holding both MDR and IVDR products, maintain two independent classification and evidence systems and do not share templates between them.
2. In IVDR project schedules, allocate explicit time for EURL sample submission and batch testing, a step that MDR experience does not include.
3. Schedule transitional periods separately for combination products under each applicable regulation, and never cover the earlier deadline of one regime with the later deadline of the other.
4. For shared systems such as the QMS, EUDAMED and UDI, verify the provision numbers separately under each regulation to avoid citing the wrong article in submissions.
5. In external documents, state clearly whether the applicable regulation is the MDR or the IVDR, and avoid the generic label of EU CE certification.

5. Verification checklist

• □ Classification systems are established separately under each Annex VIII (IVDR 7 rules versus MDR rules)
• □ Evidence systems are separated: performance evaluation (IVDR Article 56) versus clinical evaluation (MDR Article 61)
• □ Class D project plans include the EURL sample submission and testing phase
• □ Transition periods are scheduled in three steps (IVDR) and two steps (MDR) respectively
• □ Provision numbers for shared systems (QMS, EUDAMED, UDI) are verified separately under each regulation
• □ External documents state the applicable regulation and its number explicitly

Legal information verified as of 29 October 2026.

GRZAN helps manufacturers running parallel MDR and IVDR portfolios keep the two regimes properly separated: dual classification documentation, performance evaluation and PMPF programmes for IVDs, EURL sample logistics planning for Class D devices, and dual transition scheduling for legacy products. For support with cross-regime compliance planning, contact info@grzanglobal.com.